Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dersimelagon - Mitsubishi Tanabe Pharma

Next Previous
Drug Profile

Dersimelagon - Mitsubishi Tanabe Pharma

Alternative Names: [14C] MT-7117; Dersimelagon; MT-7117; MT-7117-MB

Latest Information Update: 04 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Carboxylic acids; Cyclopentanes; Fluorinated hydrocarbons; Phenyl ethers; Piperidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erythropoietic protoporphyria
  • Phase II Diffuse scleroderma
  • No development reported Autoimmune disorders

Most Recent Events

  • 29 May 2025 Mitsubishi Tanabe Pharma plans a phase I trial in healthy volunteers in China (NCT06994286)
  • 21 May 2025 Mitsubishi Tanabe Pharma completes enrollment in its phase III trial for Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA, Australia, Bulgaria, Czech Republic, France, Italy, Netherlands, Japan, Poland, Spain and the UK (PO) (NCT06144840)
  • 12 Jun 2024 Efficacy data from a phase II trial in Diffuse scleroderma presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top